0
0
BRUSSELS — In a landmark decision for metabolic health, the European Commission officially approved a higher 7.2mg maintenance dose of Novo Nordisk’s Wegovy (semaglutide) on February 17, 2026. This approval expands treatment options for adults living with obesity across all 27 EU member states, offering a potent new tool for those who have reached a weight-loss plateau on standard dosages. The decision follows a positive recommendation from the European Medicines Agency (EMA) and underscores the evolving landscape of chronic weight management.
Breaking the Plateau: The STEP UP Findings
The cornerstone of this approval lies in the results of the Phase 3b STEP UP clinical trial. This study followed 1,407 adults living with obesity over a 72-week period to evaluate whether increasing the dose beyond the previous 2.4mg ceiling would yield additional clinical benefits.
The data revealed a clear “dose-response” relationship. Participants escalated to the 7.2mg dose achieved an average weight loss of 18.7% to 21% of their total body weight. In contrast, those remaining on the standard 2.4mg dose saw an average loss of 15.6%, while the placebo group recorded only 3.9%.
Perhaps most striking was the “high-responder” category: 33.2% of participants on the 7.2mg dose lost at least 25% of their body weight, nearly doubling the 16.7% success rate seen in the 2.4mg group.
How It Works
Wegovy is a GLP-1 (glucagon-like peptide-1) receptor agonist. It functions by mimicking a natural hormone released in the gut after eating. This hormone targets areas of the brain that regulate appetite and food intake, increasing feelings of fullness while slowing stomach emptying.
“This approval represents a significant step forward for personalized obesity treatment,” says Dr. Fatima Khan, an endocrinologist at University College London Hospitals, who was not involved in the trial. “It offers clinicians a vital tool for patients who find their progress stalling. Obesity is a complex, chronic disease; having the flexibility to titrate dosage upward allows us to treat it with the same precision we apply to hypertension or diabetes.”
Safety and Tolerability
As with any medication, increased potency brings questions regarding side effects. The STEP UP trial reported that the 7.2mg dose maintained a safety profile consistent with lower doses.
-
Primary Side Effects: Mostly gastrointestinal, including nausea, vomiting, diarrhea, and constipation.
-
Timing: These symptoms typically peaked during the dose-escalation phase and subsided as the body adjusted.
-
Discontinuation: Only about 3% of participants discontinued the 7.2mg dose due to adverse events—a figure only slightly higher than the 2.4mg cohort.
The EMA concluded that the benefits—namely the reduction of obesity-related comorbidities—significantly outweigh the potential risks of gastrointestinal discomfort.
Public Health: Beyond the Scale
The implications of a 21% weight reduction extend far beyond aesthetics. For an individual weighing 110kg (approx. 242 lbs), a 21% loss translates to roughly 23kg (50 lbs). Such a reduction is clinically proven to:
-
Improve cardiovascular health and reduce the risk of heart failure.
-
Lower the incidence of Type 2 diabetes.
-
Alleviate mechanical strain on joints, specifically reducing knee osteoarthritis pain.
“While the numbers are promising, we must maintain a balanced view,” cautions Dr. Elena Rossi, an obesity specialist at the University of Milan. “We need more head-to-head data against competitors like Eli Lilly’s Zepbound (tirzepatide), which has shown high efficacy in separate trials. The goal isn’t just the highest number on the scale; it’s sustainable health.”
Access and Administration
Currently, the 7.2mg regimen involves administering three 2.4mg injections in a single sitting. However, Novo Nordisk has announced plans to release a single 7.2mg pen to simplify the process, with an expected rollout in late 2026.
Access remains a hurdle. While the EU-wide approval is a regulatory victory, actual availability will depend on national health systems and insurance coverage. Furthermore, global supply chain constraints for GLP-1 medications continue to be a challenge as demand skyrockets.
Guidelines for Consumers
Health authorities emphasize that the 7.2mg dose is not a starting point. It is intended for patients who:
-
Have been on the 2.4mg dose for at least four weeks.
-
Require additional weight reduction to meet health goals.
-
Are maintaining a reduced-calorie diet and increased physical activity.
Limitations and Future Outlook
Despite the enthusiasm, the medical community remains cautious about “muscle wasting.” The STEP UP trial noted that lifestyle interventions—specifically resistance training—are crucial to ensure that weight loss comes from fat rather than lean muscle mass. Additionally, long-term data on “weight rebound” after discontinuation remains a primary area of study.
As the US FDA undergoes an expedited review of the 7.2mg dose via a priority voucher, the global momentum for high-dose semaglutide suggests a shift toward more aggressive, long-term pharmacological management of obesity.
References
-
Reuters. (2026, February 17). EU approves higher dose of Novo Nordisk’s Wegovy.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
